Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 71
Filter
1.
Int Surg ; 100(3): 408-13, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25785318

ABSTRACT

A therapeutic guideline for sigmoid volvulus (SV) has not been established, and the most recommended surgical procedure for SV has not been determined. Our objective is to assess the usability of elective laparoscopic sigmoidectomy and the feasibility of single-incision laparoscopic surgery for SV following endoscopic reduction. SV typically affects the elderly and accounts for 1% to 7% of intestinal obstructions in Western countries. We report on 3 patients with SV who underwent elective laparoscopic sigmoidectomy following endoscopic reduction, and we first describe single-port surgery for SV. We discuss the 3 patients (a 79-year-old male, an 88-year-old female, and a 67-year-old female) with SV who underwent elective laparoscopic sigmoidectomy following endoscopic reduction. All 3 patients underwent laparoscopic sigmoidectomy, and 2 patients underwent single-port laparoscopic surgery without complications. Recurrence of volvulus was not seen during the course of 12 to 24 months. In experienced hands, elective laparoscopic sigmoidectomy after colonoscopic detorsion is a valuable alternative, and single-port surgery is also feasible.


Subject(s)
Colectomy/methods , Elective Surgical Procedures/methods , Intestinal Volvulus/surgery , Laparoscopy/methods , Sigmoid Diseases/surgery , Aged , Aged, 80 and over , Colonoscopy , Combined Modality Therapy , Female , Humans , Intestinal Volvulus/therapy , Male , Sigmoid Diseases/therapy
2.
Gan To Kagaku Ryoho ; 41(10): 1298-300, 2014 Oct.
Article in Japanese | MEDLINE | ID: mdl-25335723

ABSTRACT

A 66-year-old woman was diagnosed with pancreatic tail cancer, and she was referred to our hospital. Abdominal computed tomography(CT)revealed a tumor(2.5 cm in diameter)in the pancreatic tail, with invasion to the spleen and splenic vein. In February 2013, we performed distal pancreatectomy with splenectomy, left adrenal gland resection, and D2 lymph node dissection. Diagnostic peritoneal lavage cytology during surgery was positive; however, we performed curative resection because there were no signs of peritoneal dissemination and distant metastasis. The patient was discharged from the hospital 23 days after the operation, with good postoperative course. Histological diagnosis was pancreatic tail cancer, pT4N0H0P0M(-) fStage IVa. Subsequently, the patient received postoperative adjuvant chemotherapy(TS-1: 100mg/day, 4 courses)combined with Wilms'tumor 1(WT1)peptide-pulsed dendritic cell therapy. No serious adverse events occurred during the postoperative adjuvant therapy. The patient remains alive without recurrence 16 months after the operation.


Subject(s)
Cancer Vaccines/therapeutic use , Dendritic Cells/immunology , Immunotherapy , Pancreatic Neoplasms/therapy , Peritoneal Neoplasms/therapy , Silicates/therapeutic use , Titanium/therapeutic use , WT1 Proteins/immunology , Aged , Cancer Vaccines/immunology , Chemotherapy, Adjuvant , Combined Modality Therapy , Female , Humans , Pancreatectomy , Pancreatic Neoplasms/pathology , Peptides/immunology , Peritoneal Neoplasms/secondary
3.
Breast Cancer ; 21(6): 761-4, 2014 Nov.
Article in English | MEDLINE | ID: mdl-21728002

ABSTRACT

Liver metastases from breast cancer are generally treated with systemic therapy such as chemotherapy or hormonotherapy. However, local treatment options such as resection, radiofrequency ablation (RFA), and radiotherapy can also be considered to treat oligometastases. We report the case of a 45-year-old female treated with stereotactic body radiotherapy (SBRT) after chemotherapy against a solitary liver metastasis from primary breast cancer. A liver metastasis with diameter of 35 mm developed 3.5 years after surgery for primary breast cancer in 2004. Fourteen courses of triweekly docetaxel treatments considerably decreased the metastatic lesion, but there still remained a tiny lesion radiographically. Chemotherapy was stopped because of the side-effects of docetaxel, and then SBRT was selected for additional treatment, aiming at complete cure of metastasis. X-ray irradiation (52.8 Gy/4 fractions) was applied to the remaining metastatic lesion, and magnetic resonance imaging (MRI) showed no evidence of residual tumor 4 months after irradiation. Neither regrowth nor recurrences have been found until now, 24 months after SBRT. SBRT for oligometastases of breast cancer may be one of the possible curative-intent options, being less invasive than surgical resection or RFA.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/pathology , Liver Neoplasms/drug therapy , Liver Neoplasms/secondary , Liver Neoplasms/surgery , Radiosurgery , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Breast Neoplasms/surgery , Docetaxel , Female , Humans , Magnetic Resonance Imaging , Middle Aged , Neoplasm, Residual/surgery , Taxoids/administration & dosage , Taxoids/adverse effects
4.
Gan To Kagaku Ryoho ; 41(12): 2083-5, 2014 Nov.
Article in Japanese | MEDLINE | ID: mdl-25731430

ABSTRACT

A 67-year-old-man came to our hospital for further evaluation of a liver tumor detected by abdominal ultrasonography at another hospital. Abdominal computed tomography showed a tumor (8 cm in diameter)in the left lobe of the liver, with invasion of the left and middle hepatic veins, and multiple lymph node metastases. Liver biopsy examination revealed intrahepatic cholangiocellular carcinoma (cStage IVB). Therefore, chemotherapy with gemcitabine(GEM)was administered. The hepatic tumor and multiple lymph nodes were reduced in size after eight courses of GEM chemotherapy. In May 2013, we performed an extended left hepatectomy with biliary tract reconstruction and extended lymph node dissection. The histological diagnosis was intrahepatic cholangiocellular carcinoma, pT3N0H0P0M (-), fStage III. The patient's postoperative recovery was good, and 1 month after surgery, the patient received 6 course of postoperative adjuvant GEM chemotherapy. No serious adverse events occurred during the postoperative adjuvant therapy period. The patient is alive without recurrence 14 months after surgery and 23 months after diagnosis.


Subject(s)
Antimetabolites, Antineoplastic/therapeutic use , Bile Duct Neoplasms/surgery , Bile Ducts, Intrahepatic/surgery , Cholangiocarcinoma/surgery , Deoxycytidine/analogs & derivatives , Neoadjuvant Therapy , Aged , Bile Duct Neoplasms/drug therapy , Bile Duct Neoplasms/pathology , Bile Ducts, Intrahepatic/pathology , Biliary Tract Surgical Procedures , Cholangiocarcinoma/drug therapy , Deoxycytidine/therapeutic use , Hepatectomy , Humans , Male , Gemcitabine
5.
Gan To Kagaku Ryoho ; 41(12): 2169-71, 2014 Nov.
Article in Japanese | MEDLINE | ID: mdl-25731459

ABSTRACT

A 64-year-old man presented with a chief complaint of abdominal pain. An abdominal computed tomography (CT) scan showed a mass 30-mm in diameter at the splenic flexure, and we diagnosed a retroperitoneal abscess. Conservative therapy was successful, and the patient was discharged. However, 1 month later, he again experienced abdominal pain. To reassess the abscess, contrast-enhanced abdominal CT was performed. In addition to the retroperitoneal abscess, the CT scan showed an approximate 30-mm mass in the head of the pancreas with no contrast uptake. The abscess was also detected by endoscopic retrograde pancreatography. We suspected but could not confirm pancreatic cancer. Two months later, the patient developed obstructive jaundice. At this time, we diagnosed pancreatic cancer, and subtotal stomach-preserving pancreaticoduodenectomy was performed. The histopathologic diagnosis was pancreatic cancer, T4, N0, M0, Stage IVa. The postoperative course was favorable, and the patient received postoperative adjuvant chemotherapy. He remains alive without recurrence 15 months after surgery.


Subject(s)
Abdominal Abscess/surgery , Carcinoma, Ductal/surgery , Pancreatic Neoplasms/surgery , Abdominal Abscess/complications , Carcinoma, Ductal/complications , Carcinoma, Ductal/drug therapy , Chemotherapy, Adjuvant , Humans , Male , Middle Aged , Neoplasm Invasiveness , Pancreatic Neoplasms/complications , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/pathology , Pancreaticoduodenectomy
6.
Gan To Kagaku Ryoho ; 41(12): 2500-2, 2014 Nov.
Article in Japanese | MEDLINE | ID: mdl-25731570

ABSTRACT

Fibrin glue injection is used for treating postoperative digestive fistulas; however, this method is not always successful, especially in cases of complicated fistulas. Generally, the fibrin glue coagulates immediately after application before it reaches the end of the fistulas. Based on the results of an in vitro study of tensile strength and coagulation time, we utilized fibrin glue injection therapy with diluted thrombin solution (× 30) for treating refractory postoperative complicated fistulas in 23 cancer patients. In 20 of these patients, the fistulas were successfully closed after an average of 2.0 treatment cycles. This simple method of fibrin glue injection with diluted thrombin is useful for treating complicated postoperative digestive fistulas.


Subject(s)
Digestive System Surgical Procedures/adverse effects , Fistula/drug therapy , Neoplasms/surgery , Postoperative Complications/drug therapy , Thrombin/therapeutic use , Aged , Female , Fistula/etiology , Humans , Indicator Dilution Techniques , Injections, Intradermal , Male , Middle Aged , Thrombin/administration & dosage
7.
Gan To Kagaku Ryoho ; 40(1): 61-5, 2013 Jan.
Article in Japanese | MEDLINE | ID: mdl-23306919

ABSTRACT

The Japanese gastric cancer treatment guidelines(published as a web supplement for version 3)recommend the implementation of HER2 testing prior to the selection of chemotherapy. Since we had not yet implemented HER2 immunohistochemistry(IHC)methods for gastric cancer, we tried to compare the HER2 testing results from a reference laboratory(ref lab) and our hospital(in-house). The HER2 concordance rates were calculated between the results from in-house and ref lab using 26 cases(31 samples)which were from patients with advanced, metastatic unresectable, or Stage IV resectable gastric cancer. The HER2 expression(in-house/ref lab)was distributed as follows: negative/negative, 18 cases; negative/equivocal, 2 cases; negative/positive, 1 case;equivocal/equivocal, 2 cases; and positive/positive, 3 cases. The concordance rate was 88. 4%(23/26), and the mismatch rate was 11. 6%(3/26)between in-house and ref lab. Although IHC test results with in-house and ref lab had been generally consistent, it is still necessary to improve and standardize diagnostic accuracy in the near future.


Subject(s)
Immunohistochemistry , Receptor, ErbB-2/analysis , Stomach Neoplasms/chemistry , Adult , Aged , Female , Hospitals, General , Humans , Male , Middle Aged
8.
Gan To Kagaku Ryoho ; 40(12): 1687-9, 2013 Nov.
Article in Japanese | MEDLINE | ID: mdl-24393889

ABSTRACT

BACKGROUND: In this retrospective study, we investigated the clinical outcomes of endoscopic gastroduodenal stenting (EGDS) for gastric outlet obstruction( GOO) caused by unresectable gastric cancer( UGC). METHODS: A retrospective study was performed on 20 UGC patients with GOO between 2007 and 2012. We compared the clinical outcomes of EGDS using the WallFlex stent( GDS group, n=8) and palliative Roux-en-Y gastrojejunostomy( RYGJ group, n=12). RESULTS: The numbers of patients with a poor performance status and prior use of chemotherapy were higher in the GDS group than in the RYGJ group. No postoperative complications were observed, and the GOO score improved in both groups. The median days taken to resume oral food intake, the median duration of oral food intake, and the median survival time in the RYGJ and GDS groups were 4 and 3 days( p=0.0008), 301 and 151 days( p=0.0698), and 345 and 161 days (p=0.0070), respectively. CONCLUSIONS: EGDS for GOO caused by UGC can be performed safely even after chemotherapy and is beneficial in terms of improvement of oral food intake.


Subject(s)
Duodenum , Gastric Outlet Obstruction/therapy , Stents , Stomach Neoplasms/complications , Aged , Aged, 80 and over , Endoscopy, Gastrointestinal , Female , Gastric Bypass/adverse effects , Gastric Outlet Obstruction/etiology , Humans , Male , Middle Aged , Retrospective Studies , Stents/adverse effects , Treatment Outcome
9.
Gan To Kagaku Ryoho ; 40(12): 1853-5, 2013 Nov.
Article in Japanese | MEDLINE | ID: mdl-24393944

ABSTRACT

Twenty patients( 30 nodules) with metastatic liver cancer( MLC) and 10 cases with hepatocellular carcinoma( HCC) treated by stereotactic radiotherapy (SRT) were analyzed. SRT was administered at 48.0 or 52.8 Gy/4 Fr/1 wk. The response rate (RR) in MLC patients was 78%, and 11 patients survived longer than 1 year and 9 patients survived as long as 2 years. Clinical analysis suggests that the ideal indications for SRT in MLC are solitary nodules in patients without extrahepatic disease who have undergone systemic chemotherapy. Although RR of SRT for HCC was as high as 85%, intrahepatic recurrence was observed in all patients and 6 patients died within 1 year. Further analysis is needed to determine the indication for SRT in HCC patients.


Subject(s)
Liver Neoplasms/radiotherapy , Aged , Aged, 80 and over , Antineoplastic Agents/therapeutic use , Combined Modality Therapy , Female , Humans , Liver Neoplasms/drug therapy , Liver Neoplasms/pathology , Liver Neoplasms/secondary , Male , Middle Aged , Prognosis
10.
Gan To Kagaku Ryoho ; 39(12): 1809-11, 2012 Nov.
Article in Japanese | MEDLINE | ID: mdl-23267894

ABSTRACT

Twenty cases (27 therapeutic sites/30 nodules) of metastatic liver cancer treated with stereotactic radiotherapy (SRT)were analyzed. The original sites of cancer were colorectal(8 cases), breast(4 cases), stomach(3 cases), esophagus(2 cases), and other organs (3 cases). SRT was performed with 52.8 Gy·4 fr·-1·wk-1. The response rate was 78%, including complete response (CR) at 8 sites, partial response (PR) at 10 sites, stable disease (SD) at 2 sites, progressive disease(PD) at 3 sites, and not detected(ND) at 4 sites, thus demonstrating a potent local therapeutic effect. Ten patients survived for more than 1 year, 8 patients survived for 2 years, and 4 died before 6 months. Clinical analysis suggests that the ideal indications for SRT are patients with a solitary nodule and without extrahepatic disease who have undergone systemic chemotherapy.


Subject(s)
Liver Neoplasms/radiotherapy , Aged , Female , Humans , Liver Neoplasms/secondary , Male , Middle Aged
11.
Gan To Kagaku Ryoho ; 39(12): 2313-5, 2012 Nov.
Article in Japanese | MEDLINE | ID: mdl-23268061

ABSTRACT

We report the effects of stereotactic radiotherapy (SRT) targeting for distant solitary metastases from gastric cancer that were uncontrollable with chemotherapy. SRT(52.8 Gy per 4 fractions) was performed in 3 patients with liver metastasis and 1 patient with lung metastasis. Although SRT showed no effect in the patient with lung metastasis, complete remission from liver metastasis with cystic change was observed in all 3 patients. One patient died due to multiple liver metastasis, and the other 2 patients are alive 27 and 41 months after SRT without liver metastasis. Although pneumothorax and pleural effusion were recognized in 1 case, grade 3 or 4 adverse events were not recognized in all 4 cases. SRT showed excellent local therapeutic effects without serious complications, suggesting that this is an effective treatment for localized metastasis from gastric cancer.


Subject(s)
Liver Neoplasms/surgery , Lung Neoplasms/surgery , Radiosurgery , Stomach Neoplasms/surgery , Aged , Combined Modality Therapy , Humans , Liver Neoplasms/secondary , Liver Neoplasms/therapy , Lung Neoplasms/secondary , Lung Neoplasms/therapy , Male , Middle Aged , Neoplasm Staging , Radiosurgery/adverse effects , Recurrence , Stomach Neoplasms/pathology , Stomach Neoplasms/therapy
12.
Gan To Kagaku Ryoho ; 39(12): 2324-6, 2012 Nov.
Article in Japanese | MEDLINE | ID: mdl-23268065

ABSTRACT

We report a case of recurrent gastric cancer with paraaortic lymph nodes (No.16LNs) that was effectively controlled with chemoradiation therapy. A 63-year-old man underwent distal gastrectomy, cholecystectomy, and D2 dissection in July 2004 for advanced gastric cancer in the lower third area that was diagnosed as moderately differentiated stage II adenocarcinoma [T1(SM), N2, H0, P0, CY0, M0]. He suffered from No.16LNs metastasis with serum CEA elevation in October 2007, and therefore, 4 courses of S-1, followed by 3 courses of CPT-11 as second-line treatment, 14 courses of docetaxel as third-line treatment, and 15 courses of paclitaxel+cisplatin as fourth-line chemotherapy, were administrated. Enlargement of No.16LNs with serum CEA elevation was observed in October 2010. Other metastases were not observed, and hence, chemoradiotherapy (CRT; S-1: 80 mg/body+total of 65 Gy per 26 Fr) for No.16LNs was performed. A partial response and reduction of serum CEA level were noted, and the patient is alive with no sign of progression 18 months after CRT. Grade 1 adverse events including anemia, fatigue, and anorexia were recognized. It is thought that chemoradiation therapy is an effective treatment for localized LN metastasis originating from gastric cancer resistant to chemotherapy.


Subject(s)
Antimetabolites, Antineoplastic/therapeutic use , Chemoradiotherapy , Oxonic Acid/therapeutic use , Stomach Neoplasms/therapy , Tegafur/therapeutic use , Aorta/pathology , Drug Combinations , Humans , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Staging , Salvage Therapy , Stomach Neoplasms/pathology
13.
Gan To Kagaku Ryoho ; 39(12): 2404-6, 2012 Nov.
Article in Japanese | MEDLINE | ID: mdl-23268092

ABSTRACT

OBJECTIVE: To clarify the complications associated with subcutaneous central venous access port devices, we investigated the patients who underwent placement of central venous access port devices in our hospital. METHODS: Overall, 171 cancer patients who underwent placement of subcutaneous central venous access port devices (119 for chemotherapy and 52 for home parenteral nutrition) between February 2006 and December 2011 and who were followed up for 1 month, were retrospectively analyzed in this study. Univariate analysis was performed on complications related to clinical factors, including age, gender, insertion sites, intended purposes, duration of catheterization, surgeons, catheter materials, and use of bevacizumab. RESULTS: The mean follow-up time was 213 days (range, 31-1,873), and 35 patients (20.5%) required the port device to be extracted due to complications, including infection in 24(14.0%), wound dehiscence at the port site in 2 (1.2%), obstruction of the catheter in 6 (3.5%), catheter-induced venous thrombosis in 1 (0.6%), and catheter fracture in 2(1.2%). No statistically significant differences were observed between the frequency of complications and age, gender, insertion sites, intended purposes, duration of catheterization, surgeons, catheter materials, or use of bevacizumab. CONCLUSION: The incidences of complications related to implantation and management of these devices are relatively high and early. Patients should be followed carefully by chest radiography at regular intervals.


Subject(s)
Catheterization, Central Venous/adverse effects , Catheters, Indwelling/adverse effects , Neoplasms , Surgical Wound Infection/etiology , Adult , Aged , Aged, 80 and over , Catheterization, Central Venous/instrumentation , Female , Humans , Male , Middle Aged , Neoplasms/therapy , Retrospective Studies
14.
Gan To Kagaku Ryoho ; 38(12): 1954-6, 2011 Nov.
Article in Japanese | MEDLINE | ID: mdl-22202250

ABSTRACT

A 63-year-old male admitted for hematemesis was diagnosed with type 3 advanced gastric cancer located in the upper and middle body of the stomach in an endoscopic examination. Abdominal computed tomography demonstrated lymph nodes metastasis and a splenic vein thrombus. Since curative resection was not deemed possible, we performed neoadjuvant chemotherapy using S-1 (120 mg, day 1-21) plus CPT-11 (135 mg, day 1 and 15) except for down-staging. After 4 courses of chemotherapy, gastric tumor and metastatic lymph nodes were reduced in size and the splenic vein thrombus was disappeared, and then total gastrectomy was performed (tub2, T2 (MP) N0 H0 M0 P0 CY0, Stage IB). S-1 medication was applied as adjuvant chemotherapy. Forty months passed from the operation, the patient remains alive with no signs of relapse.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Camptothecin/analogs & derivatives , Neoadjuvant Therapy , Oxonic Acid/therapeutic use , Splenic Vein/pathology , Stomach Neoplasms/drug therapy , Tegafur/therapeutic use , Venous Thrombosis/etiology , Camptothecin/administration & dosage , Camptothecin/therapeutic use , Drug Combinations , Humans , Irinotecan , Male , Middle Aged , Neoplasm Staging , Oxonic Acid/administration & dosage , Remission Induction , Stomach Neoplasms/complications , Stomach Neoplasms/pathology , Stomach Neoplasms/surgery , Tegafur/administration & dosage , Tomography, X-Ray Computed
15.
Gan To Kagaku Ryoho ; 38(12): 2103-5, 2011 Nov.
Article in Japanese | MEDLINE | ID: mdl-22202297

ABSTRACT

A 75-year-old man was diagnosed as gall bladder carcinoma by postoperative histological examination following laparoscopic cholecystectomy. He underwent the second surgery of resection of liver bed and port sites with lymph node dissection. Isolated hepatic metastasis of 20 mm in diameter was found in S4/8 by MRI 18 months postoperatively, and stereotactic radiotherapy (52.8 Gy/4 Fr) was done for the metastatic lesion. The lesion could not be detected by CT 7 months after the radiotherapy, and thereafter no local recurrence has been observed for 24 months. However, lymph node metastasis of #9 was diagnosed 31 months postoperatively. Liniac radiotherapy (60 Gy/20 Fr)was performed and stable disease has been obtained for 9 months. The patient is alive at present of 43 months after surgery without any other site of the disease, and his quality of life is well maintained. Stereotactic radiotherapy showed an excellent local therapeutic effect without any serious complications, suggesting that this is a potent modality for isolated liver metastasis of gall bladder carcinoma.


Subject(s)
Gallbladder Neoplasms/therapy , Liver Neoplasms/radiotherapy , Stereotaxic Techniques , Aged , Gallbladder Neoplasms/pathology , Humans , Liver Neoplasms/secondary , Male , Neoplasm Staging , Remission Induction , Tomography, X-Ray Computed
16.
Gan To Kagaku Ryoho ; 38(12): 2146-8, 2011 Nov.
Article in Japanese | MEDLINE | ID: mdl-22202311

ABSTRACT

We report a case of recurrent gastric cancer that was effectively controlled with radiation therapy. A 63-year-old man underwent total gastrectomy, cholecystectomy and D2 dissection in February 2006 for early gastric cancer in the upper third area that was diagnosed with papillary adenocarcinoma and Stage IA (T1 (SM), N0, H0, P0, CY0, M0). He underwent lateral segmentectomy of the liver for liver metastasis of S2/3. He suffered from No. 12 lymph node(LN)metastasis in February 2009, so CPT-11, next to S-1, was administered. Portal tumor thrombosis (PTT) and liver S8 metastasis were observed in September 2009. First, chemoradiotherapy (CRT) ( S-1 80 mg/body+total of 65 Gy per 26 Fr) for #12 LN and PTT was performed and, in turn, stereotactic radiation therapy (SRT: total of 52.8 Gy per 4 Fr) was performed. A complete response in all of tumors was noted and he was presently alive with no sign of recurrence after 19 months after CRT and SRT. Grade 3 or 4 adverse events were not recognized. It is thought that radiation therapy is one of effective treatments for localized metastasis from gastric cancer.


Subject(s)
Stomach Neoplasms/radiotherapy , Humans , Liver Neoplasms/radiotherapy , Liver Neoplasms/secondary , Male , Middle Aged , Neoplasm Staging , Recurrence , Stomach Neoplasms/pathology , Tomography, X-Ray Computed
17.
Gan To Kagaku Ryoho ; 38(12): 2448-50, 2011 Nov.
Article in Japanese | MEDLINE | ID: mdl-22202409

ABSTRACT

A 70-year-old female suffered from jaundice was admitted to our hospital for a tumor in the pancreas head. CA19-9 and DUPAN-2 levels were increased in laboratory test. Enhanced abdominal computed tomography (CT) scan revealed a low density area of pancreas head. Cytology of pancreatic juice was performed by ERCP, and malignant cells were detected. Pancreaticoduodenectomy was performed under a diagnosis of pancreatic cancer (T3N1M0, stage III). Despite of adjuvant chemotherapy (gemcitabine) after surgery, CT scan revealed a low density area in the cut end of remnant pancreas at 3 months, which was accompanied with elevation of and CA19-9 and DUPAN-2 levels. We diagnosed as a recurrent pancreatic cancer of remnant pancreas without any other side of recurrence and re-resection was performed. Because of chylous ascites and depression following a second surgery, postoperative adjuvant chemotherapy could not be started. Re-recurrence was detected at 3 months after the second surgery, and she died 6 months after the surgery. Remnant or repeated pancreatectomy for local recurrent pancreatic carcinomas is extremely rare with limited number of cases reported in the literature. We report our experience, and discuss the significance of re-resection for recurrence of remnant pancreas.


Subject(s)
Pancreatic Neoplasms/surgery , Aged , Antimetabolites, Antineoplastic/therapeutic use , Combined Modality Therapy , Deoxycytidine/analogs & derivatives , Deoxycytidine/therapeutic use , Fatal Outcome , Female , Humans , Neoplasm Staging , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/pathology , Pancreaticoduodenectomy , Recurrence , Tomography, X-Ray Computed , Gemcitabine
18.
Jpn J Clin Oncol ; 41(6): 747-51, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21498408

ABSTRACT

OBJECTIVE: Although docetaxel is active against gastric cancer, Grade 3 or 4 neutropenia occurs in the majority of patients in Japan when administered at 60 mg/m(2) every 3 weeks. To determine a more convenient and tolerable schedule than the tri-weekly schedule, we conducted a dose-escalation study of bi-weekly docetaxel. In this study, we investigated the maximum-tolerated dose and recommended dose. METHODS: Patients with advanced gastric cancer who had received prior chemotherapy were enrolled between April 2004 and March 2007. This study was designed to evaluate the escalated dose of docetaxel starting at 35 mg/m(2) (Level 1) given every 2 weeks. The dose was escalated in a stepwise fashion to 40 mg/m(2) (Level 2), 45 mg/m(2) (Level 3) and 50 mg/m(2) (Level 4). RESULTS: Fifteen patients completed at least two cycles of the therapy. Three episodes of Grade 3 neutropenia occurred in all patients and Grade 4 neutropenia was observed at Level 4 in six patients. Grade 3 or 4 thrombocytopenia and anemia were not observed. Grade 3 aspartate aminotransferase/alanine aminotransferase elevation (n= 1) and Grade 3 stomatitis (n = 1) were noted at Level 4. There was no other Grade 3 or 4 non-hematologic toxicity. The definition of dose-limiting toxicities of this docetaxel schedule at Level 4 are Grade 4 neutropenia, Grade 3 aspartate aminotransferase/alanine aminotransferase elevation and Grade 3 stomatitis. CONCLUSIONS: The maximum-tolerated dose of docetaxel when administrated following the bi-weekly schedule was 50 mg/m(2) and the recommended dose was 45 mg/m(2). Bi-weekly administration of docetaxel may provide a better tolerated and efficacious use in gastric cancer.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Salvage Therapy/methods , Stomach Neoplasms/drug therapy , Taxoids/administration & dosage , Taxoids/adverse effects , Adult , Aged , Alanine Transaminase/blood , Anemia/chemically induced , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Aspartate Aminotransferases/blood , Disease Progression , Docetaxel , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Humans , Male , Maximum Tolerated Dose , Middle Aged , Neutropenia/chemically induced , Patient Selection , Stomach Neoplasms/blood , Stomach Neoplasms/pathology , Thrombocytopenia/chemically induced , Treatment Outcome
19.
Gan To Kagaku Ryoho ; 38(4): 581-4, 2011 Apr.
Article in Japanese | MEDLINE | ID: mdl-21498985

ABSTRACT

BACKGROUND: In our hospital, the starting dose of S-1 for patients over 75 years of age with advanced gastric cancer was determined by body surface of area, creatinine clearance, performance status(PS)and the presence of complications. The objective of this retrospective study was to investigate the proper administration of S-1 in elderly patients by comparing patients given a standard dose of S-1 to those given a reduced dose. METHODS: Twenty patients participated. Six patients were administered S-1 at a standard dose(standard group)and fourteen patients with at a reduced dose(reduced group). Safety, feasibility and anti-tumor effects were assessed. RESULTS: Three cases of grade 3 adverse events were found in the standard group, and one case was found in the reduced group. Time to treatment failure was 4. 4 months for the standard group and 8. 2 months for the reduced group. The overall response rate was 25% in the standard group and 30% in the reduced group. CONCLUSIONS: It is important to reduce S-1 administration to patients over 75 years of age with caution, and take into account the patient's renal function, PS and Ccr complications.


Subject(s)
Antimetabolites, Antineoplastic/therapeutic use , Oxonic Acid/therapeutic use , Stomach Neoplasms/drug therapy , Tegafur/therapeutic use , Aged , Aged, 80 and over , Drug Combinations , Female , Humans , Male
20.
Gan To Kagaku Ryoho ; 38(4): 643-5, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21498996

ABSTRACT

We present the case of a 58-year-old man who underwent distal gastrectomy for Stage III A advanced gastric cancer, identified as poorly-differentiated adenocarcinoma. He was diagnosed with recurrent peritoneal metastasis 11 months after surgery. S-1(80mg/m / 2)was administered as first-line chemotherapy, followed by weekly paclitaxel(80mg/m2)as secondline chemotherapy. Although a partial response was obtained, a peritoneal tumor in the upper abdomen, ascites, and an elevation in the serum carcinoembryonic antigen(CEA)level were observed. As the tumor proved resistant to paclitaxel, making the treatment ineffective, bi-weekly docetaxel(45mg/m2)was initiated. The tumor showed a partial response, the ascites disappeared, and the serum CEA level decreased. The time to progression was seven months until the appearance of ileus and ascites due to tumor re-growth. This paclitaxel-resistant gastric cancer with peritoneal recurrence proved responsive to docetaxel as third-line chemotherapy. Docetaxel may be active against gastric cancer that is resistant to paclitaxel because of the different effects of these two agents. Further clinical studies on the efficacy of docetaxel against paclitaxel-resistant gastric cancer are needed.


Subject(s)
Antineoplastic Agents/therapeutic use , Drug Resistance, Neoplasm , Salvage Therapy , Stomach Neoplasms/drug therapy , Taxoids/therapeutic use , Antineoplastic Agents/administration & dosage , Carcinoembryonic Antigen/blood , Clinical Trials, Phase III as Topic , Docetaxel , Humans , Male , Middle Aged , Neoplasm Staging , Paclitaxel/therapeutic use , Recurrence , Stomach Neoplasms/blood , Stomach Neoplasms/pathology , Taxoids/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...